Letrozole Suppresses Plasma Estradiol and Estrone Sulphate More Completely Than Anastrozole in Postmenopausal Women With Breast Cancer
- 1 April 2008
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (10) , 1671-1676
Abstract
Purpose: To compare the effects of anastrozole and letrozole on plasma estradiol (E2) and estrone sulfate (E1S) levels. Patients and Methods: Fifty-four postmenopausal women with estrogen receptor–positive breast cancer receiving aromatase inhibitors (AIs) as part of their adjuvant therapy were randomly assigned to receive either 3 months of anastrozole (1 mg) followed by 3 months of letrozole (2.5 mg), both given orally once daily, or 3 months of the opposite sequence. Blood was taken at the same time and the same day of the week from each patient, before and after 3 months of each drug, and plasma levels of E2 and E1S were determined using highly sensitive radioimmunoassays. Results: There were 27 patients in each group. The mean age of the patients was 63 years (range, 49 to 83 years). Baseline E2 levels ranged from 3 pmol/L to 91 pmol/L with a mean of 25.7pmol/L. Only one of 54 (2%) patients had an E2 value ≥ 3 pmol/L after receiving letrozole, versus 20 of 54 (37%) patients after receiving anastrozole (P < .001). Extrapolation revealed a mean E2 level after anastrozole treatment of 2.71 pmol/L (range, 2.38 to 3.08 pmol/L). Following letrozole, it was 1.56 pmol/L (range, 1.37 to 1.78 pmol/L). Mean residual E2 was 10.1% for anastrozole and 5.9% for letrozole. Residual E1S levels were 4.6% for anastrozole and 2.0% for letrozole (P = .001). Conclusion: Letrozole reduces plasma E2 and E1S levels to a significantly greater extent than anastrozole in postmenopausal women taking AIs as part of their adjuvant therapy for hormone receptor–positive breast cancer.Keywords
This publication has 22 references indexed in Scilit:
- A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast CancerNew England Journal of Medicine, 2005
- Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancerThe Lancet, 2005
- An open randomised trial of second-line endocrine therapy in advanced breast cancerEuropean Journal of Cancer, 2003
- Serum Estradiol Level and Risk of Breast Cancer During Treatment With RaloxifeneJAMA, 2002
- COMPARATIVE BIOAVAILABILITY OF LETROZOLE UNDER FED AND FASTING CONDITIONS IN 12 HEALTHY SUBJECTS AFTER A 2·5 MG SINGLE ORAL ADMINISTRATIONBiopharmaceutics & Drug Disposition, 1997
- Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphateThe Journal of Steroid Biochemistry and Molecular Biology, 1997
- Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells.The Journal of Clinical Endocrinology & Metabolism, 1995
- Arimidex : A potent and selective fourth-generation aromatase inhibitorBreast Cancer Research and Treatment, 1994
- SUPPRESSION OF RESIDUAL OESTROGEN PRODUCTION WITH AMINOGLUTETHIMIDE IN WOMEN FOLLOWING SURGICAL HYPOPHYSECTOMY OR ADRENALECTOMYClinical Endocrinology, 1984
- Estrogens Stimulate Cell Proliferation and Induce Secretory Proteins in a Human Breast Cancer Cell Line (T47D)*The Journal of Clinical Endocrinology & Metabolism, 1982